Vimta Labs will host virtual one-on-one meetings with investment analysts on Friday, July 31, 2026, to discuss its business operations. The company disclosed the schedule in a filing submitted to the stock exchanges on July 28, 2026, confirming that no unpublished price-sensitive information (UPSI) will be shared during these interactions.

The engagements are part of Vimta Labs' ongoing investor relations efforts under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III. The meetings are designed to facilitate direct dialogue between management and institutional investors regarding the company's operational performance and strategic direction.

Meeting Schedule

The company has arranged two separate time slots for the virtual sessions. Both meetings are classified as one-on-one interactions conducted via video conferencing platforms.

Pragati Khadse, Senior Portfolio Manager at Nine Rivers Capital, is scheduled to meet with company representatives in the first slot. The second slot features Avnish Tiwari, Chief Investment Officer, and Avnish Burman, Senior Investment Professional, from Vaikarya Change.

Compliance and Disclosure

Sujani Vasireddi, Company Secretary and Compliance Officer at Vimta Labs, signed the intimation letter, affirming adherence to regulatory guidelines. The filing explicitly states that the agenda for both meetings is limited to understanding the company's business operations, ensuring transparency and compliance with listing obligations.

What the Numbers Show

While this announcement does not contain financial metrics, the structured engagement with dedicated portfolio managers and chief investment officers indicates a focus on detailed operational clarity for key institutional stakeholders. The decision to host separate one-on-one sessions rather than a group call allows for tailored discussions specific to each firm's investment thesis.

Vimta Labs Limited reported a year-on-year improvement in its financial performance for the first quarter ended June 30, 2026, with total income rising 13.7% to ₹1,128.86 Mn. Net profit increased 11.4% to ₹210.42 Mn from ₹188.94 Mn in the corresponding period of the previous year. The company's EBITDA stood at ₹283.38 Mn, with margins expanding to 36.4% from 35.7% in the year-ago period, driven by healthy traction in its Pharmaceutical Research and Testing Services business. The Board of Directors approved the unaudited financial results on July 20, 2026, with statutory auditors conducting a limited review.

Financial Performance

While Q1 revenue remained steady at ₹1,128.86 Mn, reflecting 13.7% year-on-year growth, operating margins declined on a quarter-on-quarter basis. Management attributed the sequential margin compression to higher facility costs, the implementation of new labour laws, and rupee appreciation. Despite these headwinds, the company has indicated it expects no further drop in margins going forward. The Food Testing division faced ongoing global uncertainties, which the business offset through deeper domestic market penetration.

The following table summarises the key financial metrics for Q1 on a year-on-year and quarter-on-quarter basis:

Operational Highlights

The company operates through a single reportable segment, 'Contract Research and Testing Services'. During the quarter, Vimta Labs commenced operations in Biologics contract research and development services (CRADS) and secured its first domestic order for the new biologics facility. Management has indicated that the biologics facility is anticipated to significantly enhance revenue and margins starting in the third year. The company also successfully completed a regulatory audit from Ukraine during the quarter.

The Nomination and Remunerations Committee granted 40,500 stock options to eligible employees under the Vimta Labs Employee Stock Option Plan 2021. Revenue and costs included ₹0.45 million relating to lab setup services provided under a Service Concessionaire Arrangement with the Food Safety and Standards Authority of India (FSSAI). The employee benefits expense included ₹8.46 million for the quarter related to the stock option plan.

Management Outlook

Management has set an ambitious revenue growth target of 20% to 25% for the current financial year. The company expects strong inquiry trends and robust demand to boost performance in future quarters, particularly in the Pharma segment and a recovering Clinical Research business. Management also foresees business growth ahead and expects no further deterioration in margins despite the cost pressures experienced in Q1.

Earnings Call Recording

The audio recording of the Q1 FY 2026–27 Earnings Call held on July 20, 2026, is available on the company's website. The disclosure was made in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.